# Natera account plan

> Natera is a US cell-free DNA diagnostics company in oncology, women's health and organ health, with $2,306.1 million of FY2025 revenues.

## At a glance

Natera is a diagnostics company whose cell-free DNA tests detect tumour DNA (Signatera), fetal DNA (Panorama) and donor DNA in transplant rejection (Prospera), backed by carrier screening and genomic profiling. Tests run in its own CLIA laboratories in Austin, San Carlos and Boulder, and 95% of 2025 revenues came through its US direct sales force; products are also offered in over 80 countries via laboratory partners. FY2025 total revenues were $2,306.1 million (+35.9%) with a net loss of $208.2 million. It had 6,140 employees at the end of 2025, about 6,500 by November 2026, and is a US-listed company (NTRA).

## Business units

- **Oncology**: Signatera tumour-informed MRD testing, Latitude tissue-free MRD, Altera genomic profiling and Empower hereditary screening, plus early cancer detection in development. It is the fastest-growing area: about 339,500 oncology tests were processed in Q3 2026 versus about 211,000 a year earlier, and the December 2025 Foresight Diagnostics acquisition added lymphoma.
- **Women's Health**: Panorama non-invasive prenatal testing, Horizon carrier screening covering up to 835 conditions, Fetal Focus single-gene NIPT, Vistara and Anora. Panorama and Horizon generate the majority of revenues; women's health posted mid to high single-digit growth in Q3 2026.
- **Organ Health**: Prospera donor-derived cfDNA tests for kidney, heart and lung transplant rejection, covered by Medicare, and the Renasight kidney gene panel; CareDx is the primary competitor. Organ health volumes grew almost 40% in Q3 2026.
- **Constellation and licensing** (Licensing and other revenues of $10.3 million in 2025): Cloud-based bioinformatics licensed to partner laboratories, CE Marked in the EU, plus revenue from strategic partnership agreements.

## Strategic priorities

- **Grow Signatera volume and price**: Management calls the MRD market significantly underpenetrated and targets a long-term path to $2,000 Signatera ASP, from approximately $1,290 in Q3 2026, through more Medicare coverage and guideline inclusion.
- **$6 billion 2029 target**: The CEO says the 2029 target rests on oncology volume and ASP, global markets including Japan, pharma and data, and slightly more modest non-oncology growth.
- **Clinical evidence**: Natera keeps funding trials to win guidelines and coverage, with breast cancer trial investment now exceeding over $250 million and 25 abstracts at ESMO in 2026.
- **Early cancer detection**: The FIND study is fully enrolled with 30,000 patients in the PMA cohort, with a readout in 2027; the multi-cancer early detection assay received FDA Breakthrough Device designation.
- **Pharma and data services**: Pharma MRD demand in the first three quarters of 2026 was already up roughly 70% over all of 2025; management expects pharma and data to contribute several hundred million dollars in 2029.
- **Japan**: The bladder indication was approved in Q3 2026 and colorectal and bladder pricing is being discussed with the health ministry.

## Latest results

In Q3 2026 total revenues were $794.0 million, up 34.1% from $592.2 million, on higher volume and average selling prices; gross margin was 64.7% and the net loss narrowed to $59,912 thousand from $87,544 thousand. Approximately 1,093,100 tests were processed (+22.3%) and oncology tests processed rose 60.9%. Over nine months revenues were $2,243.4 million (+36.7%). Natera raised 2026 revenue guidance to $3.005 billion - $3.035 billion (previously $2.850 billion - $2.910 billion), with gross margin of approximately 64% to 66% and positive cash flow. Cash, cash equivalents and restricted cash were $1,097.2 million at September 30, 2026.

## Investments and deals

- **Foresight Diagnostics acquisition**: Closed December 4, 2025 for total consideration of $424.5 million, adding phased-variant MRD technology, lymphoma, and the Boulder laboratory.
- **R&D and clinical trials**: 2026 R&D is guided at $825 million to $925 million; Q3 2026 R&D rose 39.8% to $242,433 thousand, including early cancer detection, which the CFO calls more than $100 million in spend that generates zero revenue.
- **Signatera Genome**: An upgrade with phased and structural variants and an LOD95 below one part per million, described as the most significant upgrade to Signatera since launch.
- **Headcount and lab capacity**: Headcount increased by approximately 1,200 over the first nine months of 2026 to support lab operations, R&D, clinical trials and billing; 2025 investing included $106.2 million of property and equipment and new leases in Austin and Pleasanton.

## Challenges and risks

- **Reimbursement and prior authorisation**: Natera depends on insurers and Medicare; prior-authorisation requirements have hit billing and margins, and many payers do not reimburse microdeletions screening.
- **Litigation**: Natera is appealing a $292.5 million Guardant false-advertising verdict and a $57.0 million Ravgen patent verdict, and faces a $44.9 million CareDx verdict.
- **Competition and pricing**: It names competitors including Guardant Health, Exact Sciences, Tempus Labs, BillionToOne, Labcorp and CareDx, and may not keep its price premium; sequencers and many reagents are sole-sourced.
- **Continued net losses**: The accumulated deficit is $3.0 billion and management expects to continue to incur net losses while investing heavily.
- **LDT regulation**: Most products are laboratory developed tests exposed to possible active FDA regulation.

## What leadership says

> "you're not going to see any big radical change. We want to stick to the formula that's worked for us." — Solomon Moshkevich, Chief Executive Officer, Q3 2026 earnings call, 2026-11-05, his first as CEO

> "MRD testing is not only about finding recurrence earlier. It can also help avoid overtreatment, including major surgeries as well as systemic therapy." — Solomon Moshkevich, President (now CEO), Q1 2026 earnings call, 2026-05-07

> "We feel like we are just getting started." — Steve Chapman, then Chief Executive Officer, Q1 2026 earnings call, 2026-05-07

> "We have deployed a significant amount of AI capability around the business in the last year." — Michael Brophy, Chief Financial Officer, Q1 2026 earnings call, 2026-05-07


## Where a supplier can help

- **Billing and payer operations**: Prior authorisation and reimbursement are stated challenges and headcount was added in billing; revenue-cycle, prior-auth automation and payer-analytics tools fit.
- **Lab automation and supplies**: Volume growth above 20% and a cost focus on automation and reagent use create demand for lab automation, logistics and second-source supplies.
- **Clinical trial services**: Heavy investment in trials, from breast cancer to the FIND early detection study, opens room for CROs, site networks and trial-data platforms.
- **Pharma and real-world data**: The pharma and data push on a real-world data asset of over half a million patients needs data infrastructure, privacy and analytics partners.
- **International expansion**: The Japan launch and global markets in the 2029 target call for regulatory, market-access and distribution partners.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report on Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/1604821/000110465926020881/ntra-20251231x10k.htm)

Annual report · 2026-02-27

- Natera is a US diagnostics company built on cell-free DNA (cfDNA) technology, applied to three areas: oncology, women's health and organ health. Headquartered in Austin, Texas, with CLIA labs in Austin, San Carlos (California) and Boulder (Colorado); 6,140 employees at December 31, 2025.
- FY2025 revenues were $2,306.1 million, up 35.9% from $1,696.9 million in 2024; product revenues were $2,295.8 million. Net loss was $208.2 million (2024: $190.4 million), including $354.4 million of non-cash stock compensation.
- Volume: approximately 3.5 million tests processed in 2025 (3.1 million in 2024); oncology units processed were approximately 800,800 versus 528,200.
- The majority of revenues come from Panorama (NIPT) and Horizon (carrier screening); Signatera, the personalised ctDNA MRD test, drives oncology growth and higher ASPs.
- The business is almost entirely US: 95% of revenues via the US direct sales force, 3% via US laboratory partners, 2% international; revenues from customers outside the US were $41.8 million.
- December 2025: acquisition of Foresight Diagnostics (phased-variant MRD technology, lymphoma) for total consideration of $424.5 million, plus up to $175.0 million of contingent share consideration.
- Investment is heavy: R&D rose 54.4% and SG&A 39.9% in 2025; an early cancer detection test (initial focus colorectal cancer) is in development.
- Cash generation turned positive: $215.3 million cash from operations in 2025; $1.1 billion of cash and restricted cash at year end, $80.3 million drawn on the UBS Credit Line.
- Key risks: payer coverage and reimbursement (prior authorisation, microdeletions), competition (Guardant, Exact Sciences, Labcorp, Quest, CareDx and others), FDA regulation of LDTs, and litigation, including a $292.5 million false-advertising verdict in favour of Guardant and a $57.0 million Ravgen patent verdict.

### [Quarterly Report on Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/1604821/000162828026071145/ntra-20260930.htm)

Interim report · 2026-11-05

- Q3 2026 (quarter ended September 30, 2026): total revenues up $201.8 million or 34.1% year on year, to $793,981 thousand; net loss $59,912 thousand versus $87,544 thousand.
- Nine months 2026: revenues $2,243.4 million, up 36.7%; net loss $212.0 million versus $255.4 million; cash from operations $138,895 thousand.
- Volume: reported units up 23.0% in Q3, to approximately 1,024,800; oncology units processed approximately 339,500 versus 211,000.
- ASP up approximately 8.8% in Q3 (13.7% over nine months), driven by a higher Signatera mix and better payer coverage. Revenue true-ups (changes in estimate) fell to $32.3 million in Q3.
- R&D up 39.8% in Q3 (clinical trials including early cancer detection); SG&A up only 8.1% as legal and consulting costs fell $22.7 million.
- Headcount grew by approximately 1,200 in nine months; cash and restricted cash $1.1 billion; $80.3 million drawn on the UBS Credit Line.
- CEO change: Steve Chapman resigned as CEO, President and director effective November 5, 2026; Solomon Moshkevich (previously President, Clinical Diagnostics) became CEO and President.
- Litigation: final judgment entered in June 2026 on the $292.5 million Guardant false-advertising verdict (under appeal); Ravgen judgment ($57.0 million verdict) entered in March 2026.

### [Natera Reports Third Quarter 2026 Financial Results](https://www.natera.com/company/news/natera-reports-third-quarter-2026-financial-results/)

Interim report · 2026-11-05

- Q3 2026 total revenues $794.0 million, up 34.1% from $592.2 million; gross margin 64.7% (64.9% a year earlier).
- Tests processed approximately 1,093,100 (+22.3%); oncology tests approximately 339,500 (+60.9%); clinical MRD units up 32,700 over Q2 2026.
- Excluding revenue true-ups ($32.3 million in Q3 versus $52.3 million in Q2), non-GAAP gross margin rose 137 basis points sequentially.
- Net loss $59.9 million, or ($0.42) per diluted share, versus $87.5 million; operating expenses $576.1 million (+19.5%).
- Cash up approximately $5.7 million in the quarter, to $1,097.2 million; $80.3 million of debt.
- 2026 revenue guidance raised by $140 million at the midpoint, to $3.005 billion - $3.035 billion; gross margin approximately 64% to 66%; SG&A $1.225 billion to $1.300 billion; R&D $825 million to $925 million; cash flow positive.

### [Natera Q3 2026 Earnings Call Transcript](https://www.earningswhispers.com/transcript/NTRA/Q32026)

Executive talk · Solomon Moshkevich, Chief Executive Officer · 2026-11-05

- First call as CEO for Solomon Moshkevich (15 years at Natera); outgoing CEO Steve Chapman says revenues grew "roughly tenfold" during his almost eight years as CEO and that he stays on as a consultant and board advisor.
- New long-term goal: "double revenues in the next three years, reaching $6 billion in revenue in 2029", reached "even with minimal contribution from our emerging cancer screening business"; profitability expected if the plan is executed.
- Q3: about 1.1 million tests processed; clinical MRD units approximately 316,000 versus 202,000 (+56%); revenue $794 million, up approximately 34% (north of 40% excluding true-ups); gross margin approximately 65% (63.2% excluding true-ups).
- Signatera ASP stepped up to approximately $1,290 from $1,271; the long-term path is $2,000. CFO Brophy calls $1450 "eminently achievable" within the 2029 plan.
- New Medicare coverage for Signatera in early-stage hepatocellular carcinoma; the Japan launch (colorectal and bladder) awaits pricing, expected to be "accretive" to ASP.
- Pharma/biopharma MRD revenue for the first three quarters is already up roughly 70% over all of 2025; pharma and data should contribute "several hundred million dollars" in 2029.
- FIND colorectal screening study fully enrolled (30,000 patients in the PMA cohort), with a readout in 2027; FDA Breakthrough Device designation for the multi-cancer early detection assay.
- 2027 planning: OPEX growth of 10 to 12%, gross margin in the 2026 range, units grown by the same number as in 2026; long-term goal of 70% plus gross margin.

### [Natera (NTRA) Q1 2026 Earnings Call Transcript](https://www.fool.com/earnings/call-transcripts/2026/05/07/natera-ntra-q1-2026-earnings-call-transcript/)

Executive talk · Steve Chapman, Chief Executive Officer · 2026-05-07

- Q1 2026: revenue $697 million, 39% growth; first quarter with 1 million units delivered; 249,000 clinical oncology units (+55%), about 24,000 more than in Q4 2025.
- Gross margin just under 65% versus a 64% full-year guide; the revenue guide was reset up by more than $120 million and the gross margin midpoint raised to 65%; R&D raised by $50 million to pull forward trials.
- Fetal Focus is approaching a run rate of nearly 200,000 orders; women's health added 63,000 units from Q4 2025 to Q1 2026.
- Signatera ASP of roughly $1,250, an expected 2026 exit of roughly $1,275, and a long-term target of $2,000. Chapman: at current volumes a $2,000 ASP "would be worth something like $750 million in revenue and margin".
- Moshkevich: "MRD testing is not only about finding recurrence earlier. It can also help avoid overtreatment, including major surgeries as well as systemic therapy."
- FIND CRC screening study: enrolment complete in Q3 2026 and PMA data in 2027; Japan Signatera launch expected to "effectively double Signatera's annual CRC volume TAM".
- Breast cancer trial investment exceeds $250 million; 35 abstracts at ASCO; Foresight's phased-variant technology is driving pharma and hematology interest.

## Questions about Natera

### What does Natera do?

Natera runs cell-free DNA tests for oncology (Signatera), women's health (Panorama, Horizon) and organ health (Prospera) in its own US laboratories.

### What is Natera's revenue?

FY2025 total revenues were $2,306.1 million (+35.9%); Q3 2026 revenues were $794.0 million, and 2026 guidance is $3.005 billion - $3.035 billion.

### How many employees does Natera have?

6,140 at the end of 2025 and about 6,500 as of November 2026.

### Who leads Natera?

Solomon Moshkevich became CEO and President on November 5, 2026, succeeding Steve Chapman; co-founder Matthew Rabinowitz is Executive Chairman and Michael Brophy is CFO.

### What is Natera's strategy?

Grow Signatera volume and price through coverage and evidence, expand into Japan and pharma and data services, and develop early cancer detection, toward a $6 billion 2029 target.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
